132 related articles for article (PubMed ID: 11603001)
1. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Meredith RF; Partridge EE; Alvarez RD; Khazaeli MB; Plott G; Russell CD; Wheeler RH; Liu T; Grizzle WE; Schlom J; LoBuglio AF
J Nucl Med; 1996 Sep; 37(9):1491-6. PubMed ID: 8790200
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Forero A; Meredith RF; Khazaeli MB; Shen S; Grizzle WE; Carey D; Busby E; LoBuglio AF; Robert F
Cancer Biother Radiopharm; 2005 Oct; 20(5):467-78. PubMed ID: 16248762
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Alvarez RD; Partridge EE; Khazaeli MB; Plott G; Austin M; Kilgore L; Russell CD; Liu T; Grizzle WE; Schlom J; LoBuglio AF; Meredith RF
Gynecol Oncol; 1997 Apr; 65(1):94-101. PubMed ID: 9103398
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
8. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity.
Robert F; Busby EM; LoBuglio AF
Cancer Biother Radiopharm; 2003 Jun; 18(3):317-25. PubMed ID: 12954119
[TBL] [Abstract][Full Text] [Related]
10. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
[TBL] [Abstract][Full Text] [Related]
12. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
15. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
16. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
20. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
